How are energy investors positioned?
In a challenging market environment, Owlet Inc. (OWLT) has seen its stock price touch a 52-week low, dipping to $3.20. The company, known for its innovative health technology for infants, has faced a tough year, with its stock price reflecting a significant downturn. According to InvestingPro data, while the company maintains a healthy balance sheet with more cash than debt and impressive revenue growth of 44.5% in the last twelve months, it faces profitability challenges with negative EBITDA of -$18M. Over the past year, Owlet’s stock has experienced a decline of 20.24%, mirroring the struggles of Sandbridge Acquisition and other companies in the sector. Investors are closely monitoring the company’s performance for signs of a turnaround, even as it grapples with the pressures that have led to this year-long downward trend. InvestingPro analysis suggests the stock is currently undervalued, with analysts setting price targets significantly above current levels. Discover more insights and 6 additional ProTips for OWLT with an InvestingPro subscription.
In other recent news, Owlet Inc. reported a notable 37% increase in revenue for Q4 2024, reaching $20.5 million, and a full-year revenue of $78.1 million, marking a 45% rise from the previous year. The company’s gross margin also improved significantly to 53.5% in Q4, contributing to a full-year margin of 50.4%. Owlet launched its Owlet360 subscription service in January 2025, already attracting over 25,000 subscribers. The company projects 2025 revenue between $88 million and $92 million, with gross margins expected to range from 50% to 52%. Owlet aims for adjusted EBITDA profitability by focusing on increasing DreamSock adoption and expanding its medical channels. Additionally, the company is expanding its presence in medical and healthcare channels with its FDA-cleared BabySat device, targeting higher-risk infants. Owlet has also made strides in international markets, with Q4 2024 international revenue growing by 45% year-over-year. These developments indicate Owlet’s strategic focus on growth and operational efficiency in the pediatric health monitoring market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.